Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stockwatch: Big Pharma Strikes Back In Earnings War

Executive Summary

After a phony first week for first-quarter earnings season, the second week was one of missed estimates and reduced guidance at big biotech companies. Last week – the third week – was different again, with big pharmaceutical companies restoring some honor to the life sciences sector.

You may also be interested in...



Pfizer Split, Once Decided, Could Happen Quickly, CEO Says

Pfizer Inc. could complete a business breakup in about one year if the company decides to move forward with a split, CEO Ian Read said during the company’s first quarter sales and earnings call May 3.

Sanofi Earnings Emphasize Need For Medivation Buy

Sanofi clearly would benefit from its proposed $9.3bn purchase of Medivation Inc. based on the French company's first quarter earnings, which show a pharmaceuticals business that's suffering from competition, US drug pricing pressures and foreign currency exchange issues.

Lilly Executes Growth Strategy As New Products Drive Sales Gains

Eli Lilly & Co.'s first quarter earnings met analyst expectations with help from recently approved products, but greater growth in future years depends on a closely-watched Phase III Alzheimer's program.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC065141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel